Sit Investment Associates’s Activision Blizzard ATVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-56,387
Closed -$5.28M 562
2023
Q3
$5.28M Sell
56,387
-31,255
-36% -$2.85M 0.14% 187
2023
Q2
$7.39M Buy
87,642
+1,125
+1% +$91K 0.19% 149
2023
Q1
$7.41M Sell
86,517
-29,435
-25% -$2.29M 0.2% 148
2022
Q4
$8.88M Buy
115,952
+37,232
+47% +$2.76M 0.25% 125
2022
Q3
$5.85M Buy
78,720
+12,135
+18% +$950K 0.18% 157
2022
Q2
$5.18M Sell
66,585
-24,125
-27% -$1.88M 0.16% 164
2022
Q1
$7.27M Sell
90,710
-19,800
-18% -$1.54M 0.2% 151
2021
Q4
$7.35M Sell
110,510
-46,920
-30% -$3.21M 0.17% 166
2021
Q3
$12.2M Buy
157,430
+37,841
+32% +$3.16M 0.32% 91
2021
Q2
$11.4M Buy
119,589
+25,055
+27% +$2.37M 0.28% 108
2021
Q1
$8.79M Buy
94,534
+12,656
+15% +$1.19M 0.23% 130
2020
Q4
$7.6M Buy
81,878
+988
+1% +$80.3K 0.21% 151
2020
Q3
$6.55M Sell
80,890
-400
-0.5% -$32.5K 0.19% 155
2020
Q2
$6.17M Buy
81,290
+14,340
+21% +$1M 0.19% 147
2020
Q1
$3.98M Buy
+66,950
New +$3.97M 0.15% 175

Other funds holding ATVI

Sit Investment Associates's ATVI Position: Q4 2023 in Review

Sit Investment Associates sold out of Activision Blizzard (ATVI) in Q4 2023, closing a stake of 56,387 shares — an estimated $5.28M sold.

Sit Investment Associates first reported a position in ATVI in Q1 2020 and held it in 15 quarters. The position peaked at $12.2M in Q3 2021. 12 funds tracked by Wall St. Rank hold ATVI as of Q4 2023.

  • Sit Investment Associates reported no remaining Activision Blizzard position as of Q4 2023 after selling out during the quarter.
  • Sit Investment Associates sold 56,387 Activision Blizzard shares in Q4 2023, an estimated $5.28M.
  • Sit Investment Associates first reported a position in Activision Blizzard in Q1 2020 and held it in 15 quarters.
  • Sit Investment Associates's Activision Blizzard position peaked at $12.2M in Q3 2021.
  • 12 funds tracked by Wall St. Rank held Activision Blizzard as of Q4 2023.

Based on Sit Investment Associates's 13F filing for Q4 2023, filed 13 Feb 2024.